Stocks Health care HURA
NASDAQ · Health careTuHURA Biosciences, Inc. (HURA)
It posted a net loss of $30.6M. In fiscal 2025 capital spending exceeded operating cash flow by $27.7M. At June 30, 2026 it held $996K in cash against $3.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What TuHURA Biosciences, Inc. does
TuHURA Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HURA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$30.1M | -$0.63 | -$27.7M |
| 2024 | $0 | -$21.7M | -$1.21 | -$14.8M |
| 2024 | n/a | -$8.3M | -$0.32 | n/a |
| 2024 | $0 | -$29.3M | -$2.47 | -$12M |
| 2023 | n/a | -$14.6M | -$9.27 | n/a |
| 2022 | n/a | -$22.7M | -$25.80 | n/a |
Latest SEC filings
What TuHURA Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026New debt 8-K
- September 17, 2026New debt 8-K
- September 17, 2026
- September 16, 2026
- September 4, 2026New debt 8-K
- August 28, 2026Activist stake changed SCHEDULE 13D/A
- August 21, 2026New debt 8-K
- August 19, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 14, 2026
Questions about HURA
What does TuHURA Biosciences, Inc. do?
TuHURA Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HURA.
Is TuHURA Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.6M.
When did TuHURA Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new debt from September 24, 2026.
Similar companies
Follow HURA
Get an email when TuHURA Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow HURA: get an email when it filesWhere the numbers come from
Financial figures are the values TuHURA Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.